Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2842162 | 0.90 | TRPM8 (0.50) | TRPM8MAPTPOLBALDH1A1TP53 | |
| SCHEMBL2837947 | 0.86 | TRPM8 (0.52) | TRPM8MAPTPOLBALDH1A1TP53 | |
| SCHEMBL11884379 | 0.84 | THRA (0.53) | TRPM8MAPTPOLBALDH1A1TSHR | |
| SCHEMBL13546126 | 0.82 | ALDH1A1 (0.50) | TRPM8MAPTPOLBALDH1A1TSHR | |
| SCHEMBL3573494 | 0.81 | TRPM8 (0.52) | TRPM8MAPTPOLBALDH1A1TP53 | |
| SCHEMBL64663 | 0.77 | ALDH1A1 (0.51) | TRPM8MAPTPOLBALDH1A1TP53 | |
| SCHEMBL8628856 | 0.76 | TRPM8 (0.49) | TRPM8MAPTPOLBALDH1A1TSHR | |
| SCHEMBL27870734 | 0.76 | TRPM8 (0.46) | TRPM8MAPTPOLBALDH1A1TP53 | |
| SCHEMBL10654873 | 0.74 | CYP1A2 (0.47) | POLBALDH1A1TSHR | |
| SCHEMBL1645027 | 0.74 | ALDH1A1 (0.54) | TRPM8MAPTPOLBALDH1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8217031-B2 | Heteroaryl derivatives | NIPPON SHINYAKU CO., LTD. (JP) | 2012-07-10 | — | — | US | disclosed |
| CN-101646678-B | heteroaryl derivatives | NIPPON SHINYAKU CO LTD | 2012-05-30 | — | — | CN | disclosed |
| US-20100048537-A1 | HETEROARYL DERIVATIVES | NIPPON SHINYAKU CO., LTD. (JP) | 2010-02-25 | — | — | US | disclosed |
| EP-2141168-A1 | HETEROARYL DERIVATIVES | Nippon Shinyaku Co., Ltd. (JP) | 2010-01-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048537-A1 | HETEROARYL DERIVATIVES | OPRD1, OPRM1, OPRK1 | TRPM8 1277/4885MAPT 2608/4885POLB 3087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.